Epidemiological and Microbiological aspects of Candidozyma auris (Candida auris) in Latin America: A literature review

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2025-03-29 DOI:10.1016/j.mycmed.2025.101546

Mariana Lanna , Josefina Lovatto , João N. de Almeida Junior , Eduardo A. Medeiros , Arnaldo L. Colombo , Guillermo García-Effron

{"title":"Epidemiological and Microbiological aspects of Candidozyma auris (Candida auris) in Latin America: A literature review","authors":"Mariana Lanna , Josefina Lovatto , João N. de Almeida Junior , Eduardo A. Medeiros , Arnaldo L. Colombo , Guillermo García-Effron","doi":"10.1016/j.mycmed.2025.101546","DOIUrl":null,"url":null,"abstract":"<div><div>Candidozyma auris (Candida auris) is an emerging multidrug-resistant fungal pathogen that poses a significant public health threat worldwide, particularly in Latin America, where resources for controlling outbreaks may be limited. Since the first case was reported in Venezuela in 2012, the fungus has spread to several other Latin American countries, including Colombia, Panama, Brazil, Mexico, Chile, Peru, and Argentina, manifesting as isolated cases or outbreaks, with varying prevalence. This review provides a comprehensive overview of the epidemiology and microbiological characteristics of <em>C. auris</em> in Latin America. Using data from 2012 to 2024, we examined epidemiological trends, antimicrobial resistance patterns, and the molecular mechanisms underlying resistance in Latin American isolates. Additionally, we discuss factors that may facilitate the spread of <em>C. auris</em> in the region.</div><div>Countries near the equator tend to have higher incidences of <em>C. auris</em> and a greater prevalence of antifungal resistance. Immigration and medical tourism may further contribute to the spread of <em>C. auris</em> to southern countries. However, the lack of laboratory resources and trained personnel remains the primary risk factor for the silent dissemination of <em>C. auris</em> in the region.</div><div>Conclusions: We emphasize the urgent need for coordinated public health responses to improve laboratory capabilities in Latin American hospitals, effectively combating the spread of this pathogen.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 2","pages":"Article 101546"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523325000150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Candidozyma auris (Candida auris) is an emerging multidrug-resistant fungal pathogen that poses a significant public health threat worldwide, particularly in Latin America, where resources for controlling outbreaks may be limited. Since the first case was reported in Venezuela in 2012, the fungus has spread to several other Latin American countries, including Colombia, Panama, Brazil, Mexico, Chile, Peru, and Argentina, manifesting as isolated cases or outbreaks, with varying prevalence. This review provides a comprehensive overview of the epidemiology and microbiological characteristics of C. auris in Latin America. Using data from 2012 to 2024, we examined epidemiological trends, antimicrobial resistance patterns, and the molecular mechanisms underlying resistance in Latin American isolates. Additionally, we discuss factors that may facilitate the spread of C. auris in the region.

Countries near the equator tend to have higher incidences of C. auris and a greater prevalence of antifungal resistance. Immigration and medical tourism may further contribute to the spread of C. auris to southern countries. However, the lack of laboratory resources and trained personnel remains the primary risk factor for the silent dissemination of C. auris in the region.

Conclusions: We emphasize the urgent need for coordinated public health responses to improve laboratory capabilities in Latin American hospitals, effectively combating the spread of this pathogen.

查看原文本刊更多论文

拉丁美洲耳念珠菌（念珠菌）的流行病学和微生物学方面：文献综述

耳念珠菌（念珠菌）是一种新兴的耐多药真菌病原体，在世界范围内构成重大公共卫生威胁，特别是在控制疫情资源有限的拉丁美洲。自2012年在委内瑞拉报告首例病例以来，这种真菌已蔓延到其他几个拉丁美洲国家，包括哥伦比亚、巴拿马、巴西、墨西哥、智利、秘鲁和阿根廷，表现为孤立病例或疫情，流行程度各不相同。本文综述了拉丁美洲金黄色葡萄球菌的流行病学和微生物学特征。利用2012年至2024年的数据，我们研究了拉丁美洲分离株的流行病学趋势、抗微生物药物耐药性模式和耐药性的分子机制。此外，我们还讨论了可能促进金黄色葡萄球菌在该地区传播的因素。靠近赤道的国家往往有较高的金黄色葡萄球菌发病率和较高的抗真菌耐药性流行率。移民和医疗旅游可能进一步促进金黄色葡萄球菌向南方国家传播。然而，缺乏实验室资源和训练有素的人员仍然是该地区金黄色葡萄球菌无声传播的主要危险因素。结论：我们强调迫切需要协调公共卫生反应，以提高拉丁美洲医院的实验室能力，有效地对抗这种病原体的传播。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.